Skip to content
Clinical Trials – home

SLK-Kliniken Heilbronn GmbH

Verified siteinfo

Germany Am Gesundbrunnen 20-26, Neckargartach, 74078 Heilbronn, Germany

  • 26 trials recruiting
  • Acute myeloid leukaemia · Breast cancer female · Gastric cancer
  • Adults and children

About Specializations

SLK-Kliniken Heilbronn GmbH in Heilbronn, Germany specialises in clinical trials of conditions such as Acute myeloid leukaemia, Breast cancer female, Gastric cancer, Oesophageal adenocarcinoma, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Malignancies and Pediatric Blood Cancers

At SLK-Kliniken Heilbronn GmbH, research in Hemic and Lymphatic Diseases focuses strongly on acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. These studies are designed to improve treatment effectiveness, refine risk-adapted care, and support better outcomes for both adults and children with blood cancers.

  • Testing new treatment combinations for acute myeloid leukemia and related high-risk blood disorders
  • Improving therapy for acute lymphoblastic leukemia in children and adolescents
  • Evaluating more effective approaches for lymphoma, chronic lymphocytic leukemia, and multiple myeloma

The site’s pediatric hematology/oncology expertise supports trials that aim to make cancer treatment more precise, more effective, and better tolerated.

Lung Cancer and Respiratory Disease Research

A major part of the trial portfolio addresses Respiratory Tract Diseases and Neoplasms, especially non-small cell lung cancer, small cell lung cancer, and other advanced thoracic cancers. The research also includes idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, chronic obstructive pulmonary disease, and bronchiectasis, with the goal of improving survival, symptom control, and long-term lung health.

  • Assessing new immunotherapy and targeted approaches for non-small cell lung cancer
  • Studying treatment strategies for small cell lung cancer and advanced metastatic lung disease
  • Evaluating therapies that may slow or stabilize fibrotic lung disease and other chronic respiratory conditions

This research area combines cancer care with pulmonary medicine, reflecting a broad interest in both advanced tumors and chronic lung disorders.

Gastrointestinal and Pancreatic Cancer Trials

The site conducts substantial research in Neoplasms affecting the digestive system, including gastric cancer, gastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. These trials often focus on improving first-line treatment, extending disease control, and identifying more effective options for advanced or metastatic disease.

  • Testing new combinations for gastric and gastroesophageal junction cancers
  • Evaluating treatment strategies for colorectal cancer, including postoperative and metastatic settings
  • Studying novel options for pancreatic cancer and other hard-to-treat gastrointestinal tumors

The research activity in this field aims to improve both survival and disease-free outcomes in cancers with high unmet medical need.

Breast, Gynecologic, and Urologic Oncology

Another important focus is Neoplasms in women’s health and urologic cancers, including breast cancer, ovarian cancer, endometrial cancer, and muscle-invasive urothelial carcinoma. The trials explore ways to improve recurrence prevention, increase response rates, and refine treatment decisions for both early-stage and advanced disease.

  • Testing targeted and immunotherapy approaches in breast cancer, including hormone receptor-positive and triple-negative disease
  • Studying new options for ovarian and endometrial cancers in advanced settings
  • Evaluating bladder cancer treatments that may improve event-free survival and preserve bladder function

This research reflects a strong interest in personalized cancer care across several common and aggressive tumor types.

Precision Oncology, Rare Tumors, and Immunotherapy

The site also participates in broader oncology research across Analytical, Diagnostic and Therapeutic Techniques and Equipment, with emphasis on precision medicine and immunotherapy. Studies include biomarker-selected and tumor-agnostic approaches for advanced solid tumors, melanoma, neoplasms by site, and rare cancers such as malignant germ cell tumours and ependymoma.

  • Evaluating biomarker-driven treatments for advanced solid tumors
  • Testing immunotherapy combinations in melanoma and other difficult-to-treat cancers
  • Improving diagnosis and treatment planning for selected rare tumors and pediatric brain tumors

This area highlights a modern research approach that links tumor biology with more individualized treatment strategies.

Cardiovascular and Other Non-Oncology Studies

In addition to cancer research, the portfolio includes trials in Cardiovascular Diseases such as atherosclerotic cardiovascular disease and heart failure. These studies are aimed at reducing major cardiovascular events, improving long-term disease management, and exploring new therapeutic options for patients with chronic heart conditions.

  • Assessing therapies intended to lower risk in atherosclerotic cardiovascular disease
  • Studying treatment approaches for heart failure
  • Exploring preventive strategies for patients with elevated cardiovascular risk

This adds a broader internal medicine dimension to the clinical research environment at the site.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Am Gesundbrunnen 20-26, Neckargartach74078 HeilbronnGermany
Recruiting now
26 trials
Conditions studied
70
Partner status
Verified site

More sites in HeilbronnGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

62 clinical trials

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.